Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan G Kermode

Showing results (111-120 of 120) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 120 results.
Journal of Neurology, Neurosurgery, and Psychiatry|May 28, 2017
Incidence and prevalence of NMOSD in Australia and New ZealandWajih Bukhari, Kerri M Prain, Patrick Waters, et al.
Frontiers in Neurology|July 3, 2020
Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal VariationElham Khalilidehkordi, Laura Clarke, Simon Arnett, et al.
CNS Drugs|April 4, 2026
Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort StudyIzanne Roos, Sifat Sharmin, Serkan Ozakbas, et al.
NPJ Digital Medicine|July 24, 2025
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical dataAshkan Pirmani, Edward De Brouwer, Ádám Arany, et al.
Annals of Neurology|December 23, 2011
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility lociNikolaos A Patsopoulos, , , et al.
Journal of Neurology|April 19, 2026
Predicting disease progression in multiple sclerosis with clinically accessible information and technologyTom A N Fuchs, Menno M Schoonheim, Eva M M Strijbis, et al.
Journal of Neurology|February 3, 2026
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registryAmira Souissi, Francesco Patti, Tim Spelman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 20, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort studyIzanne Roos, Sifat Sharmin, Dana Horakova, et al.
JAMA Neurology|April 14, 2025
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Nature|August 12, 2011
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis, , Stephen Sawcer, et al.
Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
Journal of Neurology, Neurosurgery, and Psychiatry|May 28, 2017
Incidence and prevalence of NMOSD in Australia and New ZealandWajih Bukhari, Kerri M Prain, Patrick Waters, et al.
Frontiers in Neurology|July 3, 2020
Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal VariationElham Khalilidehkordi, Laura Clarke, Simon Arnett, et al.
CNS Drugs|April 4, 2026
Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort StudyIzanne Roos, Sifat Sharmin, Serkan Ozakbas, et al.
NPJ Digital Medicine|July 24, 2025
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical dataAshkan Pirmani, Edward De Brouwer, Ádám Arany, et al.
Annals of Neurology|December 23, 2011
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility lociNikolaos A Patsopoulos, , , et al.
Journal of Neurology|April 19, 2026
Predicting disease progression in multiple sclerosis with clinically accessible information and technologyTom A N Fuchs, Menno M Schoonheim, Eva M M Strijbis, et al.
Journal of Neurology|February 3, 2026
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registryAmira Souissi, Francesco Patti, Tim Spelman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 20, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort studyIzanne Roos, Sifat Sharmin, Dana Horakova, et al.
JAMA Neurology|April 14, 2025
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Nature|August 12, 2011
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis, , Stephen Sawcer, et al.
Pageof 12